A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor

Trial Profile

A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Nov 2017 Results of an investigator-initiated post hoc analysis (n=237) assessing an alternative cut-off for definition of partial response able to predict clinical benefit from treatment with sunitinib in patients diagnosed with pancreatic neuroendocrine tumours using individual data of patients from the phase II [NCT00056693] and phase III [NCT00428597] trials, published in the British Journal of Cancer.
    • 03 Jun 2008 Status changed from active, no longer recruiting to completed.
    • 18 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top